Section Arrow
Quote
MIST.NASDAQ
- Milestone Pharmaceuticals
Quotes are at least 15-min delayed:2025/06/05 15:15 EDT
Last
 1.73
+0.08 (+4.85%)
Day High 
1.76 
Prev. Close
1.65 
1-M High
1.76 
Volume 
680.84K 
Bid
1.73
Ask
1.74
Day Low
1.6406 
Open
1.7 
1-M Low
1.095 
Market Cap 
88.22M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.55 
20-SMA 1.39 
50-SMA 1.21 
52-W High 2.75 
52-W Low 0.6254 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.77/-0.85
Enterprise Value
142.44M
Balance Sheet
Book Value Per Share
-0.11
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.11
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0405-0.0056-12.15%-- 
CLRBCellectar Biosciences0.3926-0.0691-14.97%-- 
RXRXRecursion Pharmaceuticals4.535-0.375-7.64%-- 
SCNIScinai Immunotherapeutics Ltd.2.89+0.37+14.68%1.21PE
OCGNOcugen0.975+0.0878+9.90%-- 
Quotes are at least 15-min delayed：2025/06/05 15:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal sprayto be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.